Alharbi et al., 2021 - Google Patents
Prevalence of colorectal cancer biomarkers and their impact on clinical outcomes in Riyadh, Saudi ArabiaAlharbi et al., 2021
View HTML- Document ID
- 13103399630330320509
- Author
- Alharbi A
- Bin Dokhi H
- Almuhaini G
- Alomran F
- Masuadi E
- Alomran N
- Publication year
- Publication venue
- PLoS One
External Links
Snippet
Objectives KRAS, NRAS, and BRAF mutations are commonly present in colorectal cancer (CRC). We estimated the frequency of KRAS, NRAS, and BRAF mutations and assessed their impact on survival and other clinical variables among Saudi patients. Design …
- 201000011231 colorectal cancer 0 title abstract description 41
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Makki | Diversity of breast carcinoma: histological subtypes and clinical relevance | |
Ahmadi et al. | Hürthle cell carcinoma: current perspectives | |
Mulligan et al. | Identification and validation of an anthracycline/cyclophosphamide–based chemotherapy response assay in breast cancer | |
Zhou et al. | Galectin-9 expression predicts favorable clinical outcome in solid tumors: a systematic review and meta-analysis | |
Thyagarajan et al. | Mitochondrial DNA copy number is associated with breast cancer risk | |
Zhang et al. | A seven-microRNA expression signature predicts survival in hepatocellular carcinoma | |
Sung et al. | Diagnostic ureterorenoscopy is associated with increased intravesical recurrence following radical nephroureterectomy in upper tract urothelial carcinoma | |
Hamada et al. | CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study | |
Cheng et al. | Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features | |
Meyer et al. | BRCA2 mutations and triple-negative breast cancer | |
Alharbi et al. | Prevalence of colorectal cancer biomarkers and their impact on clinical outcomes in Riyadh, Saudi Arabia | |
Su et al. | Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets | |
Legendre et al. | Pathway implications of aberrant global methylation in adrenocortical cancer | |
Hou et al. | Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy | |
Nozawa et al. | Synchronous and metachronous lung metastases in patients with colorectal cancer: a 20-year monocentric experience | |
Yeh et al. | Concurrent preoperative presence of hydronephrosis and flank pain independently predicts worse outcome of upper tract urothelial carcinoma | |
Tan et al. | Glycolysis-related LINC02432/hsa-miR-98–5p/HK2 axis inhibits ferroptosis and predicts immune infiltration, tumor mutation burden, and drug sensitivity in pancreatic adenocarcinoma | |
Salas et al. | Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer | |
Sakurai et al. | Depletion of skeletal muscle mass adversely affects long-term outcomes for men undergoing gastrectomy for gastric cancer | |
Hua et al. | A meta-analysis of the relationship between RARβ gene promoter methylation and non-small cell lung cancer | |
Martinez-Useros et al. | UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept | |
Muench et al. | A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile | |
Dong et al. | Upregulated WTAP expression in colorectal cancer correlates with tumor site and differentiation | |
Ha et al. | Survival outcomes according to adjuvant treatment and prognostic factors including host immune markers in patients with curatively resected ampulla of Vater cancer | |
Xiao et al. | Association between P16INK4a promoter methylation and ovarian cancer: a meta-analysis of 12 published studies |